Dr. Jean-Christophe Leroux
Full Professor at the Department of Chemistry and Applied Biosciences
Deputy Head of Institute of Pharmaceutical Sciences, ETH Zürich
Abstract
Three-dimensional (3D) printing is a versatile technology enabling the cost-effective production of personalized medical devices. Among various 3D printing methods, digital light processing (DLP) stands out for its ability to rapidly create objects with high precision. However, the fabrication of bioresorbable medical devices using DLP is in part limited by the limited choice of suitable biomedical inks. In this study, we developed innovative polyester-based inks enabling DLP printing of therapeutic devices with adjustable mechanical characteristics and degradation profiles. The most promising materials were utilized to design biodegradable customized airway stents. These stents degraded into soft hydrogels in vitro and completely disappeared seven weeks after insertion in rabbits. Additionally, the 3D printed stents could be loaded with drugs like levofloxacin or nintedanib, and their release kinetics could be tailored by modifying the copolymer composition. Furthermore, we engineered near-infrared (NIR) light-responsive stents containing gold nanorods using tunable ink compositions. This allowed for the creation of shape-memory stents that expand upon NIR light activation, facilitating easy deployment. Lastly, DLP served as a prototyping method for the fabrication and optimization of mucosal suction patches investigated for transbuccal drug delivery. These studies open new perspectives for the rapid manufacturing of complex devices with superior properties.
Speaker Bio
Jean-Christophe Leroux is a full professor of Drug Formulation and Delivery at the Institute of Pharmaceutical Sciences at the ETH Zurich, Switzerland. He has made important fundamental and applied contributions to the fields of biomaterials and drug delivery and has been involved in the development of innovative bio-detoxification systems for the treatment of metabolite disorders. He is a fellow of the AAPS, EURASC, French Academy of Pharmacy, and the CRS, and the co-founder of the start-up pharmaceutical companies Versantis AG, Inositec AG and OBaris AG.